The forkhead box m1 (Foxm1) transcription factor is essential for initiation of carcinogeninduced liver tumors; however, whether FoxM1 constitutes a therapeutic target for liver cancer treatment remains unknown. In this study, we used diethylnitrosamine/phenobarbital treatment to induce hepatocellular carcinomas (HCCs) in either WT mice or Arf -/-Rosa26-FoxM1b Tg mice, in which forkhead box M1b (FoxM1b) is overexpressed and alternative reading frame (ARF) inhibition of FoxM1 transcriptional activity is eliminated. To pharmacologically reduce FoxM1 activity in HCCs, we subjected these HCC-bearing mice to daily injections of a cell-penetrating ARF 26-44 peptide inhibitor of FoxM1 function. After 4 weeks of this treatment, HCC regions displayed reduced tumor cell proliferation and angiogenesis and a significant increase in apoptosis within the HCC region but not in the adjacent normal liver tissue. ARF peptide treatment also induced apoptosis of several distinct human hepatoma cell lines, which correlated with reduced protein levels of the mitotic regulatory genes encoding polo-like kinase 1, aurora B kinase, and survivin, all of which are transcriptional targets of FoxM1 that are highly expressed in cancer cells and function to prevent apoptosis. These studies indicate that ARF peptide treatment is an effective therapeutic approach to limit proliferation and induce apoptosis of liver cancer cells in vivo.
Introduction
Human hepatocellular carcinoma (HCC) is the fifth most common cancer, yet it is among the most lethal cancers worldwide because late detection and high frequency of tumor recurrence render current HCC therapy ineffective (1) . The primary etiology of human HCC involves HBV and HCV infections, which are primarily responsible for the high incidence of HCC in Africa and Asia and increasing occurrence of HCC in Europe and America (1) . Persistent hepatic infection by either human HBV or HCV results in chronic hepatic inflammatory injury and activation of hepatic stellate cells, which oversecrete collagen, leading to hepatic fibrosis, cirrhosis, and subsequent development of HCC (1) . Other causes of human HCC involve hepatic damage and fibrosis resulting from iron or copper deposition, alcohol, or nonalcoholic steatohepatitis (NASH, or fatty liver disease) as well as exposure to the potent hepatic carcinogen aflatoxin B1 produced by specific strains of mold (1) .
Activation of the Ras/MAPK signaling pathway drives cellcycle progression by temporal expression of cyclin regulatory subunits, which activate their corresponding cyclin-dependent kinases (CDKs) through complex formation and phosphorylate substrates critical for cell-cycle progression (2) . Development of cancer is a multistep process involving gain-of-function mutations that activate the Ras/MAPK and PI3K/Akt signaling pathways that stimulate cell-cycle progression and enhance cell survival (2, 3) . Cancer progression also requires inactivation of tumor suppressor genes that function to arrest cell proliferation in response to oncogenic stimuli (4) . In mouse models of liver cancer, loss-of-function mutations in the p53 tumor suppressor gene or gain-of-function mutations in either the Ras/MAPK, PI3K/Akt, or TGF-α signaling pathways are known to stimulate formation of HCC tumors (5) (6) (7) . A well-established mouse liver tumor induction and promotion protocol is available and consists of a single postnatal injection of the DNA-damaging diethylnitrosamine (DEN; tumor initiator) and continuous administration of the tumor promoter phenobarbital (PB) (8) . Gene expression profiling studies demonstrated that mouse HCCs induced by DEN treatment express genes similar to those found in the poorer survival group of human HCCs (9) , supporting the relevance of using DEN-induced mouse liver tumors as a model for the study of human liver tumors.
Expression of the alternative reading frame (ARF) tumor suppressor protein is induced in response to oncogenic stimuli and prevents abnormal cell proliferation through a p53-dependent G 1 cell-cycle arrest by increasing stability of the p53 tumor suppressor through nucleolar targeting of the p53 ubiquitin ligase protein Mdm2 (10) . The ARF protein also mediates p53-independent cell-cycle arrest, as the mouse ARF protein targets both the E2F1 and c-Myc transcription factors to the nucleolus, thus preventing their transcriptional activation of S-phase-promoting target genes (11) (12) (13) (14) . Loss of ARF function is a critical event for tumor promotion, as evidenced by extinguished expression of the ARF protein in a variety of tumors through DNA methylation and silencing of the ARF promoter region (4).
The mammalian forkhead box (Fox) family of transcription factors consists of more than 50 mammalian proteins (15, 16) that share homology in the winged helix DNA-binding domain (17, 18) . Expression of FoxM1 (or FoxM1b) is ubiquitous in all proliferating mammalian cells, and its expression is induced during the G 1 phase of the cell cycle and continues during S-phase and mitosis (19) (20) (21) (22) (23) . FoxM1b transcriptional activity requires activation of the RAS/MAPK pathway and binding of activated CDK-cyclin complexes to the activation domain, which mediate phosphorylation-dependent recruitment of the CREB-binding protein (CBP) transcriptional coactivator (24) . Liver regeneration studies that used the albumin promoter/enhancer cre recombinase (Alb-Cre) transgene to mediate hepatocyte-specific deletion of the mouse Foxm1 LoxP/LoxP targeted allele (Foxm1 fl/fl ) demonstrated that Foxm1 is required for hepatocyte DNA replication and mitosis (25) . Foxm1-deficient hepatocytes accumulate nuclear levels of the CDK inhibitor (CDKI) proteins p21 Cip1 and p27 Kip1 (8, 25) because FoxM1 regulates expression of S-phase kinase-associated protein 2 (Skp2) and CDK subunit 1 (Cks1) proteins (26) , which are involved in targeting these CDKI proteins for degradation during the G 1 /S transition (27) . For G 2 /M progression, FoxM1 regulates transcription of cyclin B1 and the Cdk1-activating Cdc25B phosphatase (25, 28) , and FoxM1 is essential for transcription of the mitotic regulatory genes polo-like kinase 1 (PLK1), aurora B kinase, survivin, centromere protein A (CENPA), and CENPB (26, 29, 30) .
We previously used the Alb-Cre transgene to conditionally delete the mouse Foxm1 fl/fl allele in hepatocytes prior to DEN/PB liver
Figure 1
The mouse Foxm1 transcription factor is required for hepatic tumor progression. (A) Diagram depicting experimental design of conditional deletion of Foxm1 fl/fl in preexisting liver tumors. See Methods for details of DEN/PB treatment of mice to induce HCCs as described previously (8) . To create the Foxm1 CKO, mice were injected with synthetic dsRNA to induce expression of the Mx-Cre recombinase transgene (Mx-Cre) to delete the mouse Foxm1 fl/fl targeted allele at 30 weeks after DEN/PB treatment, and the mice were then subjected to 10 additional weeks of PB tumor promotion and were labeled with BrdU as described in Methods. Controls included dsRNA-treated tumor induction. FoxM1-deficient hepatocytes failed to proliferate and were resistant to the development of hepatic tumors (8, 31) . This tumor resistance was associated with increased nuclear levels of the CDKI protein p27 Kip1 and undetectable levels of the CDK1 activator Cdc25B phosphatase (8, 31) . The FoxM1 transcription factor was identified as a novel inhibitory target of the mouse ARF tumor suppressor, and structure-function studies demonstrated that amino acid residues 26-46 of the mouse ARF protein were sufficient to inhibit FoxM1 (8) . Furthermore, treatment of osteosarcoma U2OS cells with a cell-penetrating ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide containing 9 N-terminal d-arginine (D-Arg) residues (WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] ) (32, 33) significantly reduced FoxM1 function in this cancer cell line (8) . Moreover, we previously developed Tg mice in which the Rosa26 promoter was used to drive ubiquitous expression of the human FoxM1b cDNA, and increased FoxM1b levels stimulated proliferation of pulmonary cells in response to lung injury (34) and stimulated development and progression of prostate cancers in both TRAMP/Rosa26-FoxM1b and LADY/Rosa26-FoxM1b double-Tg mice (35) .
In this study, we used the Mx promoter-driven Cre recombinase (Mx-Cre) transgene (36) to conditionally delete the Foxm1 fl/fl allele in preexisting mouse liver tumors induced by DEN/PB treatment and demonstrated that FoxM1 is required for tumor progression of hepatic cancer cells. We show that administering the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide to mice following DEN/PB exposure is an effective treatment to diminish Foxm1 function in vivo, causing selective HCC apoptosis and reduced proliferation and angiogenesis in HCC regions. We also show that Arf -/-Rosa26-FoxM1b Tg mice, in which FoxM1b is overexpressed and ARF inhibition of FoxM1 transcriptional activity is eliminated, developed highly proliferative liver tumors following DEN/PB exposure. We showed that WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment of these Arf -/-Rosa26-FoxM1b Tg mice efficiently diminished HCC proliferation and selectively induced apoptosis of the HCC region.
Results
The mouse Foxm1 transcription factor is required for hepatic tumor progression. We previously showed that conditional deletion of Foxm1 in hepatocytes prior to DEN/PB liver tumor induction is sufficient to inhibit hepatic tumor initiation (8, 31) . Here, we determined that Foxm1 is required for hepatic tumor progression. In order to do so, we used the IFN-α/β-regulated Mx-Cre transgene (36) to conditionally knock out (CKO) or delete the Foxm1 fl/fl targeted allele in preexisting liver tumors induced by the DEN/PB exposure (8) . We induced HCC in mice with 30 weeks of DEN/PB exposure, and then induced Mx-Cre expression with synthetic double-stranded RNA (dsRNA) to CKO the Foxm1 fl/fl targeted allele. Mice were then subjected to an additional 10 weeks of PB tumor promotion protocol ( Figure 1A ). To achieve long-term BrdU labeling of the liver tumors, the mice were then given drinking water containing 1 mg/ml of BrdU for 4 days (8, 37) . The Mx-Cre transgene efficiently deleted the Foxm1 fl/fl targeted allele, as evidenced by the absence of detectable nuclear staining of FoxM1 protein in liver tumors of dsRNA CKO Mx-Cre Foxm1 -/-mice compared with control liver tumors ( Figure 1, B-D) .
We used liver sections stained with H&E to determine the number of tumors per square centimeter of liver tissue (Figure 1 , E-G). To calculate the area or size of liver tumors, we used micrographs of H&E-stained liver tumor sections taken with an Axioplan 2 microscope (Zeiss) and the AxioVision program (version 4.3; Zeiss). After 40 weeks of DEN/PB exposure, control mice displayed hepatic adenomas and HCCs that were larger than 2 mm 2 in size ( Table 1) . Deletion of Foxm1 in preexisting hepatic tumors in dsRNA CKO Mx-Cre Foxm1 -/-mice caused a significant reduction in the number of liver tumors larger than 2 mm 2 in size compared with control liver tumors after 40 weeks of DEN/PB exposure ( Table 1) . We next measured tumor cell proliferation by determining the number of hepatic tumor cells that immunostained positive for BrdU incorporation ( Figure 1 , H-J). Compared with controls, dsRNA CKO Mx-Cre Foxm1 -/-mice displayed an 80% reduction in the number of liver tumor cells that stained positive for BrdU after 40 weeks of DEN/PB treatment ( Figure 1K ). Taken together, these results indicate that deletion of Foxm1 in preexisting liver tumors significantly diminished proliferation and growth of hepatic cancer cells.
The cell-penetrating WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide targets the endogenous mouse FoxM1 protein to the nucleolus of hepatic tumor cells. We previously synthesized a cell-penetrating ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide fused to 9 N-terminal D-Arg residues (32, 33) , which efficiently transduced into osteosarcoma U2OS cells and inhibited FoxM1b transcriptional activity (8) . Treatment of U2OS cells with 12 μM of (D-Arg) 9 -ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] (WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] ) peptide fluorescently tagged with tetramethylrhodamine (TMR) targeted nuclear GFP-FoxM1b green fluorescence colocalized with red WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] (D-Arg) 9 -ARF [37] [38] [39] [40] [41] [42] [43] [44] (mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] ) peptide ( Figure 2E ), which lacked the amino acids 26-37 required to interact with the FoxM1b protein (8) . Because Arg-rich sequences are sufficient for nucleolar targeting (38) , the mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide fluorescence also localized to the nucleolus of U2OS cells ( Figure 2F ). We did not observe any signal in the absence of the ARF peptide (data not shown). Dose-response curve determined that only i.p. injection of 5 mg/kg body weight or greater of the TMR fluorescently tagged WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide was detectable in cytoplasm and nucleolus of hepatocytes and in hepatic mesenchymal cells at 24 hours after administration ( Figure 2G ; see Methods). After 32 weeks of DEN/PB liver tumor induction, we subjected Foxm1 fl/fl mice to daily i.p. injections of 5 mg/kg body weight of the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide or mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide for 4 weeks and of WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide for 8 weeks (Figure 2A ). After 4 weeks of treatment with TMR fluorescently tagged ARF peptides, laser confocal microscopy of paraffin-embedded mouse liver tumor sections revealed that ARF peptide fluorescence localized to the hepatocyte cytoplasm and nucleolus ( Figure 2 , H and I) and was uniformly distributed throughout the liver parenchyma (data not shown). The FoxM1 protein staining in WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-treated liver tumor sections was partially localized to the nucleolus in hepatic tumor cells ( Figure 2L , black arrows), which was similar to the immunostaining pattern of the nucleolar protein nucleophosmin (NPM; Figure 2J , black arrows). In contrast, mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide-or PBS-treated liver tumor cells displayed only nuclear FoxM1 staining (compare Figure 2K and Figure 2M , red arrows). These studies demonstrate that the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide reduces in vivo function of FoxM1 by partially targeting the endogenous FoxM1 protein to the nucleolus of hepatic tumor cells.
WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide diminishes proliferation and size of liver tumors. We next determined the number of hepatic tumor cells that incorporated BrdU in mice treated with WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide, mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide, or PBS. Significant reduction in BrdU incorporation was found in liver tumors that had been treated with the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide for 4 or 8 weeks compared with mouse liver tumors treated with mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] (Table 1) . These results indicate that treatment with the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide is an effective method with which to reduce proliferation and growth of HCCs.
We previously demonstrated that tumor resistance in Foxm1 -/-hepatic tumors was associated with persistent nuclear accumulation of the CDKI protein p27 Kip1 (8) . WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-treated HCC cells displayed increased nuclear levels of the p27 Kip1 protein, which were similar to those found with dsRNA CKO Mx-Cre Foxm1 -/-liver tumors ( Figure 4 , B and E). In contrast, p27 Kip1 immunostaining was predominantly cytoplasmic in mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide-or PBS-treated mouse HCCs ( Figure 4 , A, C, D, and F). These studies indicate that the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide is effective in reducing FoxM1 function in vivo and that nuclear accumulation of p27 Kip1 protein was associated with reduced hepatic tumor proliferation.
WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide causes selective apoptosis of hepatic tumor cells. Analysis of H&E-stained liver tumor sections from mice treated with the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide revealed that many of the hepatic We used a fluorescence-based TUNEL assay to determine that mouse HCC cells treated with WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide exhibited a significant, 22% increase in apoptosis ( Figure 6 , A, B, and E). In contrast, very few apoptotic HCC cells were found after treatment with mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] DEN/PB treatment induced highly proliferative HCCs in Arf -/-Rosa26-FoxM1b Tg mice that were responsive to WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment. We previously showed that the ARF tumor suppressor targets the FoxM1b protein to the nucleolus and inhibits its transcriptional function (8) . Furthermore, we showed that increased expression of the human FoxM1b cDNA in Rosa26-FoxM1b Tg mice (34) stimulated development and progression of prostate cancers in both TRAMP/Rosa26-FoxM1b and LADY/Rosa26-FoxM1b doubleTg mice (35) . In order to develop a new genetic model of HCC that is highly dependent on the FoxM1b transcription factor, we crossed the [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide exhibited a 42% increase in apoptosis ( Figure 7K ), which was twice as high as in liver tumors from WT mice ( Figure 6E ). Furthermore, TUNELpositive cells were restricted to the HCC region (white arrowheads) and were not detected in adjacent normal liver tissue ( Figure 7I ). In contrast, very few apoptotic HCC cells were found after treatment of Arf -/-Rosa26-FoxM1b Tg mice with mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide or PBS (Figure 7 , G, H, and K). These Arf -/-Rosa26-FoxM1b Tg liver tumor studies show that the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide is effective in diminishing BrdU labeling of highly proliferative HCC cells and selectively induces apoptosis of HCC cells in these mice without damaging adjacent normal liver tissue.
WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide inhibits angiogenesis of the HCC region. Angiogenesis is critical to mediating HCC growth, and the endothelial Figure 8D ). In contrast, expression of the CD34 protein was not detected in the HCC region from WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-treated mice ( Figure 8C ). These results suggest that WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment was preventing HCC angiogenesis, which was likely caused by apoptosis of new HCC endothelial cells ( Figure 6B ; small apoptotic cells). In order to determine whether WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide induces apoptosis of endothelial cells, we treated human microvascular endothelial cells (HMEC-1 cells) for 48 hours with 100 μM of WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide or mutant ARF 37-44 peptide or with PBS and then assayed for apoptosis as described in Methods. This analysis revealed that WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment induced a significant increase in apoptosis of HMEC-1 cells compared with treatment with mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide or PBS ( Figure 8E ). These studies suggest that WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide is able to induce apoptosis of endothelial cells, which contributes to WT ARF peptidemediated reduction in HCC angiogenesis.
Reduced levels of the antiapoptotic survivin protein contribute to WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-induced HCC apoptosis. We have shown that FoxM1 regulates transcription of survivin (26) , which complexes with aurora B kinase to mediate its proper localization during mitosis (42) (43) (44) . Survivin is also a member of the inhibitor of apoptosis (IAP) protein family and is selectively overexpressed in tumor cells to prevent their apoptosis (45) (46) (47) (48) . Mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide-or PBS-treated liver tumors displayed abundant nuclear and cytoplasmic staining of survivin protein ( Figure 8 , E and F), and survivin expression was restricted to the mouse HCC region (data not shown). Nuclear levels of survivin were diminished in HCC regions from WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-treated and dsRNA CKO Mx-Cre Foxm1 -/-mice ( Figure 8, G and H) . Western blot analysis revealed that Foxm1 -/-liver tumors displayed a 60% decrease in expression of survivin protein (Figure 8, I and J), and no apoptosis was detected in these FoxM1-deficient liver tumors (Figure 1, E-G) . A more drastic, 90% decrease in survivin protein levels was found in hepatic tumors from WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-treated mice (Figure 8, H-J) . Our hepatoma data presented below (Figure 9 ) support the hypothesis that WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment results in hypomorphic levels of FoxM1 activity, which reduces expression of mitotic regulators to levels that are insufficient to properly execute mitosis leading to apoptosis, whereas depleting FoxM1 levels leads to mitotic arrest.
The nucleolar nucleophosmin/B23 (NPM/B23) protein (49, 50) (Figure 8 , J and K, and data not shown), suggesting that the ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide sequence was insufficient to influence their expression levels in vivo. The proapoptotic Bcl-2 family member p53-upregulated modifier of apoptosis (PUMA) is a transcriptional target gene of p53 that is essential for both p53 transcriptional and cytoplasmicdependent apoptosis (52) (53) (54) (55) . Western blot analysis showed that neither WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide nor mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment caused significant change in expression of PUMA in liver tumor extracts ( Figure 8K ), suggesting that this apoptosis of HCC cells did not involve the p53/PUMA proapoptotic pathway.
WT ARF peptide-induced apoptosis of human hepatoma HepG2 cells correlates with diminished expression of survivin, PLK1, and aurora B kinase. We used the TUNEL assay to determine that human hepatoma HepG2 cells ( Figure 9 , A-E), PLC/PRF/5 cells that express mutant p53 protein, and p53-deficient Hep3B cells exhibited 50% apoptosis after 24 hours of treatment with 25 μM of WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide (Figure 9E ), whereas only low levels of apoptosis were detected in these cells following treatment with mutant ARF 37-44 peptide or PBS ( Figure 9E ). Diminished levels of p53 protein through p53 siRNA silencing of HepG2 cells did not influence apoptosis in response to WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment ( Figure 9F ). In addition, p53 protein levels were unaltered in HepG2 cells after 24 hours of treatment with WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] or mutant ARF 37-44 peptide ( Figure 9F ). Furthermore, protein expression of the p53 downstream proapoptotic target PUMA was unchanged in HepG2 cells in response to increasing concentrations of the WT ARF 26-44 peptide ( Figure 9I ). These results suggest that WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-induced apoptosis was independent of the p53/PUMA proapoptotic pathway (52) (53) (54) (55) . Moreover, HepG2 cells in which FoxM1 levels were depleted by electroporation of FoxM1 no. 2 siRNA duplexes were resistant to apoptosis in response to WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment ( Figure 9F ), suggesting that induction of apoptosis by the WT ARF peptide was dependent on FoxM1 levels.
Tumor cells are known to express high levels of the mitotic regulators PLK1, aurora B kinase, and survivin proteins, which function to prevent their apoptosis (45, 48, (56) (57) (58) (59) (60) (61) (62) . Previous studies demonstrated that U2OS cells transfected with siFoxM1 #2 duplex were blocked in mitotic progression and exhibited undetectable levels of FoxM1 and its downstream target mitotic regulators PLK1, aurora B kinase, and survivin (26) . Consistent with these studies, FoxM1-depleted HepG2 cells exhibited undetectable protein levels of survivin, PLK1, and aurora B kinase ( Figure 9G ). We electroporated HepG2 cells with siFoxM1 #2 or control p27 Kip1 siRNA (siP27) and grew the cells in culture for 2 days to allow for siRNA silencing, and then 2 × 10 5 HepG2 cells were plated in triplicate, and viable HepG2 cells were counted at 2, 3, 4, or 5 days following electroporation. These cell-growth studies showed that FoxM1-deficient HepG2 cells were unable to grow in culture and gradually detached from the plate with time in culture ( Figure 9H ). In contrast, HepG2 cells treated with WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide exhibited a less severe reduction in levels of survivin (50%), PLK1 (80%), and aurora B kinase (80%) proteins compared with controls ( Figure 9I) . We also determined a growth curve of HepG2 cells at 1, 2, or 3 days following treatment with WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide, mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide, or PBS. Although the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-treated HepG2 cells displayed 50% apoptosis ( Figure 9E ), they were able to sustain the number of cells initially plated (2 × 10 5 ), suggesting that the WT ARF peptide-treated cells were able to proceed through the cell cycle ( Figure 9J ). These results are consistent with recent studies in which hypomorphic levels of FoxM1 protein (40% of WT FoxM1 levels) in breast cancer cell lines transfected with a different Foxm1 siRNA duplex reduced expression of mitotic regulators to levels that are insufficient to properly execute mitosis, leading to mitotic catastrophe and apoptosis (63) . Based on these findings, we propose the hypothesis that WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment causes hypomorphic levels of FoxM1 activity, leading to apoptosis, whereas depleting FoxM1 levels results in mitotic arrest. However, we have not ruled out other possibilities.
Discussion
Patients with HCCs have poor prognoses because late detection and high frequency of tumor recurrence render current HCC therapy ineffective (1). One of the potentially curative approaches in HCC therapy is based on interfering with HCC progression by blocking cell division and selectively inducing tumor cell apoptosis. In this study, we demonstrated that FoxM1 is required for proliferation of mouse liver cancer cells during tumor progression. To pharmacologically reduce in vivo activity of FoxM1 in HCC, mice were subjected to daily injections with a cell-penetrating ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide inhibitor of FoxM1 function. After 4 weeks of ARF peptide treatment, FoxM1 protein was partially localized to the nucleolus of HCC cells, and these hepatic tumor cells displayed reduced proliferation and angiogenesis with selective induction of HCC apoptosis ( Figure 9K ). Reduced tumor cell proliferation in Foxm1-deficient and WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-treated tumors was associated with nuclear accumulation of the CDKI protein p27 Kip , which is known to negatively regulate proliferation of HCC cells in mouse liver cancer models (64) . In contrast, mice treated with the cell-penetrating mutant ARF [37] [38] [39] [40] [41] [42] [43] [44] peptide, which is missing ARF sequences required for interaction with the FoxM1 protein (8), did not change nuclear localization of FoxM1 protein and failed to influence proliferation, apoptosis, or angiogenesis of HCC cells. Our current studies show that treatment with the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide effectively diminishes proliferation and induces apoptosis of HCC cells by reducing FoxM1 function in vivo.
In order to develop a new genetic model of HCC that is highly dependent on FoxM1b transcription factor, we crossed Rosa26-FoxM1b Tg mice, which ubiquitously expressed the human FoxM1b cDNA transgene (34) , into the Arf -/-mouse background. Use of the Arf -/-Rosa26-FoxM1b Tg mice allowed us to overexpress the FoxM1b protein and eliminated ARF tumor suppressor inhibition of the FoxM1b protein. After 33 weeks of DEN/PB treatment, Arf -/-Rosa26-FoxM1b Tg mice exhibited highly proliferative HCC cells that displayed approximately 30-fold more BrdU incorporation than that found in WT mice in which liver tumors were induced by DEN/PB exposure. After 4 weeks of treatment with the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide, the Arf -/-Rosa26-FoxM1b Tg mice exhibited a significant reduction in BrdU incorporation, and apoptosis was induced in twice the number of HCC cells. The results suggest that these highly proliferative hepatic tumors with increased levels of FoxM1b protein are more susceptible to WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-induced apoptosis and display diminished proliferation of HCC cells.
Increased expression of antiapoptotic survivin protein in human HCC and stage II colorectal carcinomas correlates with reduced apoptosis, poor patient outcome, and tumor recurrence follow- ing treatment (46) (47) (48) . Proliferating tumor cells are known to constitutively express high levels of the mitotic regulators PLK1, aurora B kinase, and survivin proteins, while normal cells only express these proteins in the G 2 phase and mitosis. Experiments that reduced expression of these mitotic regulators with siRNA transfection or reduced their activity with specific kinase inhibitors caused increased apoptosis and diminished growth of cancer cells (45, 48, (56) (57) (58) (59) (60) (61) (62) . We found that HCC regions and HepG2 cells expressed high levels of PLK1, aurora B kinase, and survivin, all of which are FoxM1 transcriptional target genes (26) . Previous studies demonstrated that Foxm1 -/-mouse embryonic fibroblasts or FoxM1-depleted U2OS cells were blocked in mitotic progression, failed to undergo apoptosis, and were associated with undetectable levels of PLK1, aurora B kinase, and survivin (26) . Interestingly, we showed that WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment induced significant apoptosis in human hepatoma HepG2 cells, PLC/PRF/5 cells that express mutant p53 protein, and p53-deficient Hep3B cells. We also showed that siRNA silencing of FoxM1 levels in HepG2 cells reduced apoptosis in response to WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment, suggesting that ARF-dependent apoptosis of this hepatoma cell line required FoxM1 expression. Furthermore, we showed that FoxM1-depleted HepG2 cells failed to grow in culture and displayed undetectable levels of the mitotic regulators PLK1, aurora B kinase, and survivin proteins ( Figure 9 ). In contrast, treatment of HepG2 cells with the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide resulted in less drastic reductions in expression of survivin, PLK1, and aurora B kinase protein and allowed growth of HepG2 cells in culture but resulted in a significant induction of apoptosis ( Figure 9 ). Consistent with these findings, published studies demonstrated that hypomorphic levels of FoxM1 protein (40% of WT FoxM1 levels) in breast cancer cell lines transfected with a different Foxm1 siRNA duplex reduced expression of mitotic regulators to levels that are insufficient to properly execute mitosis, leading to mitotic catastrophe and apoptosis (63) . Taken together, our results suggest that WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment of cancer cells results in partial inhibition of Foxm1 activity, leading to mitotic catastrophe and apoptosis caused by reducing expression of the mitotic regulators PLK1, aurora B kinase, and survivin proteins to levels that are insufficient for proper mitotic progression.
Angiogenesis of HCC cells is a critical event that serves to increase blood supply to the growing tumor, and CD34 protein is expressed on new sinusoid-like endothelial cells of HCC capillaries (39) (40) (41) . Mice treated with our WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide failed to develop new CD34-positive endothelial cells in HCC capillaries ( Figure 8C ), whereas HCC angiogenesis was not affected in dsRNA CKO Mx-Cre Foxm1 -/-mice. One explanation for the difference between these mice is that the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide may also be inducing apoptosis of CD34-positive endothelial cells in HCC capillaries, thus preventing angiogenesis of HCC regions required for tumor growth and expansion ( Figure 9K ). This is supported by the fact that WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment induces apoptosis of HMEC-1 cells in vitro ( Figure 8E ). Although the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide induces apoptosis of HepG2 cells in vitro, we cannot rule out the possibility that this WT ARF peptide is also inducing apoptosis of HCC cells by preventing tumor angiogenesis, thus limiting blood supply required for efficient growth of HCCs.
The WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide sequences required to inhibit Foxm1 function do not completely overlap with ARF coding regions essential to inactivating other cell-cycle regulators. For example, both amino acid regions 1-14 and 26-37 of the ARF protein are required for association and nucleolar targeting of the p53-negative regulator Mdm2 protein (65) and the NPM/B23 protein (49, 50) . Consistent with the specificity of our WT ARF peptide treatment of mice, we found no changes in liver tumor expression of Mdm2, p53, or NPM/B23 proteins in vivo, and apoptosis was independent of increased expression of PUMA, a p53 target gene required for mediating apoptosis (52) (53) (54) (55) . The ARF tumor suppressor protein also mediates nucleolar targeting of both the proliferation-specific E2F1 and c-Myc transcription factors (11) (12) (13) (14) . However, there is no overlap with our WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide sequence or the ARF sequences necessary for association with the E2F1 (ARF sequences 6-10 and 21-25) protein (66) and c-Myc (ARF sequences 1-14) protein (12) . Cotransfection assays in U2OS cells demonstrated that expression constructs containing ARF 26-37 sequences were unable to effectively inhibit FoxM1b transcriptional activity, suggesting that inhibition of FoxM1 function requires the entire ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide sequence (data not shown). Furthermore, the in vitro experiments with FoxM1-deficient HepG2 cells showed a clear relationship between FoxM1 and WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide-mediated apoptosis. Moreover, a recent study has shown that translation initiation produces an ARF protein product initiating at methionine amino acid residue 45 and that this N-terminal-truncated ARF protein is localized to the mitochondria and induces caspase-independent cell death (67) . Because these ARF 26-44 peptide sequences are not contained within this N-terminal-truncated ARF polypeptide, the WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide utilizes a mechanism that is distinct from the caspase-independent function of this N-terminal-truncated ARF peptide. Based on these studies, the WT ARF 26-44 peptide will specifically reduce Foxm1 function in vivo to limit growth of HCC and induce HCC apoptosis without diminishing the function of other known inhibitory targets of the ARF tumor suppressor protein.
After i.p. injection, the absorbed WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide enters the portal circulation and then flows to the hepatic sinusoid capillaries, which are lined with fenestrated endothelial cells that allow efficient delivery of the ARF peptide to the underlying hepatocytes and hepatic mesenchymal cells (68) . However, WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide treatment of mice did not cause side effects because it could not transverse the endothelial cell barrier of blood vessels to intestinal, colonic, pulmonary, pancreatic, or kidney epithelial cells (data not shown). Likewise, ARF peptide fluorescence also remained in the vessel endothelial cells of bone marrow, spleen, and thymus yet was undetectable in the hematopoietic cells of these organs, which correlated with normal distribution of white and red blood cells in mice treated with this WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide (data not shown). Administration of WT ARF [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] peptide by i.p. injection is therefore a selective method for hepatic delivery of this ARF peptide in vivo to limit liver tumor progression and selectively induce apoptosis of HCC cells. tions (separated by 1 day) of 250 μg of synthetic sRNA polyinosinic-polycytidylic acid [poly(I-C); Sigma-Aldrich] (36) to induce expression of the Mx-Cre transgene and cause deletion of the Foxm1 fl/fl allele in preexisting liver tumors. We continued PB administration in the drinking water for an additional 10 weeks to allow tumor growth. Livers from mice sacrificed by CO2 asphyxiation were dissected and paraffin embedded for histological staining or immunostaining and for isolation of protein extracts as described previously (8) . All protocols used in this study were approved by the animal protocol committee at the University of Illinois at Chicago.
Methods
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Treatment of mice with DEN/PB-induced liver tumors with WT ARF26-44 peptide or mutant ARF37-44 peptide.
Genemed Synthesis Inc. synthesized the WT ARF26-44 peptide (rrrrrrrrrKFVRSRRPRTASCALAFVN) or mutant ARF37-44 peptide (rrrrrrrrrSCALAFVN), both of which contain 9 N-terminal D-Arg (r) residues (32, 33) and which are TMR fluorescently tagged (red) at the N-terminus. We chose to i.p. inject mice with this cell-penetrating WT ARF26-44 peptide to efficiently deliver this peptide to the liver in vivo. In order to determine the effective concentration of dose of the ARF peptide for efficient liver delivery, mice were subjected to i.p. injection of 0.1, 1, 5, or 10 mg/kg body weight of TMR fluorescently tagged WT ARF26-44 peptide and were sacrificed 24 hours later, after which their livers were dissected, formalin fixed, and paraffin embedded as described previously (25) . Liver sections were treated with xylene to remove paraffin wax and then examined by fluorescence microscopy for red peptide fluorescence. This dose-response curve determined that i.p. injection of either equal to or greater than 5 mg/kg body weight of TMR fluorescently tagged WT ARF26-44 peptide was detectable in cytoplasm and nucleolus of hepatocytes and in hepatic mesenchymal cells at 24 hours after injection. Based on these studies, hepatic tumors were induced in Foxm1 fl/fl mice by 32 weeks of DEN/PB exposure, and then they were subjected to daily i.p. injections of 5 mg/kg body weight of the WT ARF26-44 peptide or mutant ARF37-44 peptide for 4 weeks and with WT ARF26-44 peptide for 8 weeks. After 33 weeks of DEN/PB treatment, Arf -/-Rosa26-FoxM1b Tg mice were subjected to daily i.p. injections of 5 mg/kg body weight of the WT ARF26-44 peptide or mutant ARF37-44 peptide for 4 weeks. Liver tumor-bearing mice were also administered sterile PBS as controls.
BrdU labeling, immunohistochemical staining, and TUNEL apoptosis assay. To monitor hepatic cellular proliferation, PB was removed 4 days prior to the completion of the experiment, and mice were placed on drinking water with 1 mg/ml of BrdU for 4 days before they were sacrificed (8, 37) . Hepatic tumor cell DNA replication in liver sections was determined by immunohistochemical detection of BrdU incorporation as described previously (8) . We used an affinity-purified rabbit polyclonal antibody specific to FoxM1b protein (1:500 dilution), which was generated against amino acids 365-748 of the human FoxM1b protein as described previously (26) . We also used the following antibodies specific to the mouse anti-BrdU (Bu20a, 1:100; Dako), rabbit anti-cleaved caspase-3 (5A1, 1:100; Cell Signaling Technology), rabbit anti-survivin (1:250; Novus Biologicals), mouse anti-Kip1/p27 (1:100; BD Biosciences), and rat anti-CD34 (RAM34, 1:100; BD Biosciences) for immunohistochemical detection of 5-μm liver sections using methods described previously (8, 23, 25, 29) . To measure apoptosis in mouse livers, we used the TUNEL assay on liver sections using the ApopTag Fluorescein In Situ Apoptosis Detection Kit from Intergen according to the manufacturer's recommendations. We calculated the mean number (±SD) of TUNEL-or DAPI-positive hepatocyte nuclei per 1,000 cells or ×200 field by counting the number of positive hepatocyte nuclei using 5 different ×200 fields of liver tumor sections from male mice at the indicated times of DEN/PB exposure. We used 5 liver tumor sections from 3 mice to calculate the mean number of BrdU-positive cells (±SD) per square millimeter liver tumor. To calculate the area or size of liver tumors, we used micrographs of H&E-stained liver tumor sections taken by an Axioplan 2 microscope (Zeiss) and the AxioVision program (version 4.3; Zeiss).
Western blot analysis. For Western blot analysis, 75 μg of total protein extracts prepared from liver were separated on SDS-PAGE and transferred to a PVDF membrane (Bio-Rad) as described previously (25) . The following commercially available antibodies and dilutions were used for Western blotting: mouse anti-Plk-1 (F-8, 1:500; Santa Cruz Biotechnology Inc.), mouse anti-p53 (FL-393, 1:500; Santa Cruz Biotechnology Inc.), mouse anti-MDM2 (SMP14, 1:500; Santa Cruz Biotechnology Inc.), mouse anti-β-actin (AC-15, 1:5,000; Sigma-Aldrich), mouse anti-aurora B kinase/AIM-1 (1:1,000; BD Biosciences), rabbit anti-survivin (1:2,000; Novus Biologicals), mouse anti-PUMA (1:1,000; Cell Signaling Technology), and mouse anti-NPM/B23 (1:15,000; Zymed). The primary antibody signals were amplified by HRPconjugated secondary antibodies (Bio-Rad) and detected with Enhanced Chemiluminescence Plus (ECL Plus; Amersham Biosciences). Western blot analysis was performed with liver extracts from 2-4 mice per indicated time point following DEN/PB treatment, and signal intensities were normalized to β-actin signals. Quantitation of expression levels was determined with tiff files from scanned films using the BioMax 1D software program (Kodak).
Treatment of doxycycline-inducible U2OS C3 cells with WT ARF26-44 peptide or mutant ARF37-44 peptide.
We previously reported on the generation and growth of an osteosarcoma U2OS clone C3 cell line (U2OS C3 cells) that allowed doxycycline-inducible (Dox-inducible) expression of the GFP-FoxM1b fusion protein (24) . For induced expression of the GFP-FoxM1b fusion protein, we added 1 μg/ml of Dox (Sigma-Aldrich). In order to determine the FoxM1b localization in U2OS C3 cells, they were treated with 12 μM of the TMR fluorescently tagged WT ARF26-44 or mutant ARF37-44 peptide for 24 hours. U2OS C3 cells were fixed with 10% buffered formalin (Fisher Scientific) for 20 minutes at room temperature and rinsed with PBS, and cover glasses were mounted with VECTASHIELD Mounting Medium with DAPI (catalog H-1200; Vector Laboratories). Immunofluorescence was detected using an Axioplan 2 microscope.
Treatment of human hepatoma cell lines with WT ARF26-44 or mutant ARF37-44 peptide and siRNA transfection. HepG2 cells were plated on 100-mm plates in Ham's F-12 medium supplemented with 10% FCS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM l-glutamine, and 0.5 U Humulin (insulin; Lilly). HepG2 cells were treated with 12 μM, 25 μM, or 50 μM of WT ARF26-44 peptide or mutant ARF37-44 peptide for 24 hours and used to prepare whole-cell protein extracts using the NP40 lysis buffer as described previously (26) , and Western blot analysis was performed as described above. HepG2 cells were treated with 25 μM of WT ARF26-44 peptide or mutant ARF37-44 peptide for 24 hours, and HepG2 cell apoptosis was determined by TUNEL assay using the ApopTag Fluorescein In Situ Apoptosis Detection Kit from Intergen according to the manufacturer's recommendations. We calculated the percent apoptosis of HepG2 cells (±SD) by counting the number of TUNEL-positive cells (green fluorescence) per 1,000 nuclei as visualized by DAPI (blue fluorescence) counterstaining.
Human hepatoma PLC/PRF/5 and Hep3B cell lines (ATCC) were grown as a monolayer on 100-mm plates in DMEM supplemented with 10% FCS, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 2 mM l-glutamine. Human hepatoma PLC/PRF/5 and Hep3B cells were treated with 25 μM of WT ARF26-44 peptide or mutant ARF37-44 peptide for 24 hours, and cells undergoing apoptosis were determined by TUNEL assay as described above.
Transfection of human cells with FoxM1 siRNA duplexes (Dharmacon RNA Technologies), named siFoxM1 no. 1 (CAACAGGAGUCUAAU-CAAG) and siFoxM1 no. 2 (GGACCACUUUCCCUACUUU), efficiently depleted FoxM1 levels as described previously (26) . We also previously used the human p27 Kip1 siRNA duplex (GUACGAGUGGCAAGAGGUGUU) as a control siRNA, which did not influence expression of the FoxM1 gene (26) . Human p53 siRNA duplex was purchased from Cell Signaling Technology Inc. These siRNA duplexes were transfected into HepG2 cells using the Nucleofector II apparatus and buffers recommended by the manufacturer (Amaxa Biosystems). Forty-eight hours after electroporation to allow siRNA silencing, HepG2 cells were treated with 25 μM of WT ARF26-44 peptide or mutant ARF37-44 peptide for 24 hours and then examined for apoptosis by TUNEL assay. HepG2 cells were harvested at 72 hours after FoxM1 siRNA or p27 siRNA transfection to prepare protein extracts for Western blot analysis to examine expression of PUMA, survivin, PLK1, and aurora B kinase proteins as described above. HepG2 cells were harvested at 48 hours after p53 siRNA transfection or at 72 hours after p53 siRNA transfection and examined for apoptosis as described above.
Treatment of HMEC-1 cells with WT ARF26-44 or mutant ARF37-44 peptide.
HMEC-1 cells (ATCC) were grown as monolayer cultures on 100-mm plates in MCDB 131 medium supplemented with 15% FCS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 10 ng/ml EGF (Sigma-Aldrich), and 1 μg/ml hydrocortisone (Sigma-Aldrich). HMEC-1 cells were treated for 48 hours with 100 μM of WT ARF26-44 peptide or mutant ARF37-44 peptide and then examined for apoptosis as described above.
Growth curve of HepG2 cells electroporated with FoxM1 or p27 Kip1 siRNA or treated with WT or ARF peptide. HepG2 cells were electroporated with 100 nM of FoxM1 (FoxM1 no. 2) or p27 Kip1 (siP27) siRNA duplexes (26) using the Nucleofector II apparatus (Amaxa Biosystems) and eletroporation buffers recommended by the manufacturer for HepG2 cells. HepG2 cells were replated for 2 days to allow siRNA silencing of FoxM1 or p27 Kip1 levels, and then 2 × 10 5 HepG2 cells were plated in triplicate, and viable HepG2 cells were counted at 2, 3, 4, or 5 days following electroporation. Mock-electroporated cells were used as controls. We also plated 2 × 10 5 HepG2 cells in triplicate, and viable HepG2 cells were counted at 1, 2, or 3 days following treatment with 50 μM of WT ARF26-44 peptide or mutant ARF37-44 peptide. After 2 days in culture, media was replaced with 50 μM of WT ARF26-44 peptide or mutant ARF37-44 peptide. PBS-treated cells were used as controls.
Statistics. We used the Microsoft Excel program to calculate SD and statistically significant differences between samples using the 2-tailed Student's t test. The asterisks in each graph indicate statistically significant changes with P values calculated by Student's t test: *P < 0.05, **P ≤ 0.01, and ***P ≤ 0.001. P values less than 0.05 were considered statistically significant.
